Whitepaper: SARS-CoV-2 vaccines and biosafety
Upholding biosafety standards in coronavirus vaccine development and manufacturing despite the acute worldwide need.
Patient safety comes first. This is particularly important for vaccines, which are also used on healthy individuals. On the basis of the regulatory framework, this article focuses on some of the main challenges in proving that a vaccine is both safe in principle and manufactured in a way that ensures patient safety. It also points to some general obstacles that stand in the way of vaccine development.
Related content from this organisation
- Pursuing new paths in targeted protein degradation drug development
- Efficient shutdown recovery: leveraging RMM to unlock value and ensure environmental quality
- Improved outcome for prostate cancer patients in Phase III PROpel trial
- Testing non-inferiority for accuracy of quantitative microbiological methods
- QA/QC Microbiology/RMM In-Depth Focus 2022